Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Shield Therapeutics plc    STX   GB00BYV81293

SHIELD THERAPEUTICS PLC

(STX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shield Therapeutics: Peer Teva Pharmaceutical Industries Withdraws Oppositions to Patents

10/19/2020 | 03:00am EST

By Matteo Castia

Shield Therapeutics PLC said Monday that competitor Teva Pharmaceutical Industries Ltd. has withdrawn all its oppositions against the company's patents.

"Teva has withdrawn both its appeal against the European Patent Office's decision with regard to Shield's patent number 2668175, which covers a 'process for preparing an iron hydroxypyrone' and their opposition with regard to Shield's patent number 3160951 which covers 'crystalline forms of ferric maltol," the pharmaceutical company said.

This means that both patents are maintained and will continue to provide protection, Shield said.

Write to Matteo Castia at matteo.castia@dowjones.com

(END) Dow Jones Newswires

10-19-20 0259ET

Stocks mentioned in the article
ChangeLast1st jan.
SHIELD THERAPEUTICS PLC 0.46% 108.5 Delayed Quote.-39.66%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 3.31% 9.98 Delayed Quote.-1.43%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 0.99% 3171 Delayed Quote.-9.88%
All news about SHIELD THERAPEUTICS PLC
10/19SHIELD THERAPEUTICS : Peer Teva Pharmaceutical Industries Withdraws Oppositions ..
DJ
09/17SHIELD THERAPEUTICS : Interim Results 2020
PU
09/16SHIELD THERAPEUTICS : Half-year Report Interim Report for the six months ended 3..
PU
08/07SHIELD THERAPEUTICS : Shield provides the headline results from the reanalysis o..
AQ
06/18SHIELD THERAPEUTICS : Results of 2020 Annual General Meeting
PU
06/03SHIELD THERAPEUTICS : Feraccru®/Accrufer® publications
PU
05/28SHIELD THERAPEUTICS : Investor presentations
PU
05/26SHIELD THERAPEUTICS : Appointment of Chairman
PU
05/22SHIELD THERAPEUTICS : 2019 Annual Report and 2020 AGM Notice
PU
05/22SHIELD THERAPEUTICS : Preliminary Results for the Year Ended 31 December 2019
AQ
More news
Financials
Sales 2020 9,78 M 13,2 M 13,2 M
Net income 2020 -0,29 M -0,39 M -0,39 M
Net cash 2020 3,06 M 4,11 M 4,11 M
P/E ratio 2020 -417x
Yield 2020 -
Capitalization 127 M 172 M 171 M
EV / Sales 2020 12,7x
EV / Sales 2021 19,0x
Nbr of Employees 20
Free-Float 26,9%
Chart SHIELD THERAPEUTICS PLC
Duration : Period :
Shield Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIELD THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Average target price 275,00 GBX
Last Close Price 108,50 GBX
Spread / Highest target 223%
Spread / Average Target 153%
Spread / Lowest Target 84,3%
EPS Revisions
Managers
NameTitle
Timothy William Watts Chief Executive Officer & Director
Hans-Peter Hasler Non-Executive Chairman
Peter Llewellyn-Davies Independent Non-Executive Director
Rolf K. Hoffmann Independent Non-Executive Director
Christian Schweiger Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIELD THERAPEUTICS PLC-39.66%172
GILEAD SCIENCES, INC.-6.34%76 628
VERTEX PHARMACEUTICALS3.62%58 951
REGENERON PHARMACEUTICALS32.85%53 359
WUXI APPTEC CO., LTD.67.28%39 880
BIONTECH SE250.30%29 157